Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
1(50.0%)
Phase 3
1(50.0%)
2Total
Phase 2(1)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT00561990Phase 2Completed

Nimotuzumab in Adults With Pancreatic Cancer

Role: lead

NCT00561691Completed

Nimotuzumab in Children With Intrinsic Pontine Glioma

Role: lead

NCT00753246Phase 3Completed

Nimotuzumab in Adults With Glioblastoma Multiforma

Role: lead

NCT00561873Completed

Nimotuzumab in Children With HGG

Role: lead

All 4 trials loaded